Quick-Med Technologies Inc (QMDT)

[gemstone57]

Thank you let's see it thru to a BUCK

[Penny Stocks 2.0]

20 Year Time Line, U.S. ARMY Connection is HUGE....Contracts, Funding & Awards.

[Penny Stocks 2.0]

TOP PRIZE For INDUSTRIAL RESEARCH The new research contract builds on Quick-Med's prior work developing a dressing that was shown to speed healing of vesicant (blister) injuries caused by chemical weapons (sulfur mustard gas). This previous research, which was conducted under Phase 1 and Phase 2 SBIR awards from the US Army, was presented at the 2011 Annual Meeting of the Wound Healing Society, where it received the top prize for Industrial Research and Development. This new award permits Quick-Med to extend that research to more directly address unmet commercial needs in treatments for the approximately 2.4 million thermal burns occurring annually in the US, with a dressing designed to reduce scarring and contracture in healing of severe burns. Part of the research will be conducted at the University of Florida's Institute for Wound Research

[Penny Stocks 2.0]

Quick-Med Technologies Awarded Contract to Develop Wound Healing Technology to Control Scar Contracture in Burn Patients
NIMBUS Technology Selected by Department of Defense for Advanced Wound Healing Technology SBIR Grant
Marketwired May 22, 2013 8:00 AM
Canadian Hotels Starting at $40 a Night
trivago Sponsor
?
GAINESVILLE, FL--(Marketwired - May 22, 2013) - Quick-Med Technologies, Inc. (QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a contract by the U.S. Department of Defense for research on the "Development of Technologies to Control Scar Contracture after Burn Injuries." NIMBUS technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of the DoD Defense Health Program (DHP). The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts on the basis of scientific merit and commercial potential.

The Phase I objective of this research is "to design a new innovative technology to intervene during the wound healing process, including inflammatory, proliferative and/or remodeling stages, to attenuate/control scar contracture and retain skin aesthetics following deep tissue burn injuries." The Phase I research contract is valued at about $150,000. Work starts immediately and is expected to take about 6 months. Follow-on phases of the award can bring the total value close to $1M, and will develop the proof of concept to commercial readiness.

"We are very pleased to have been competitively selected for this important advanced research program into dressings that can speed wound healing," said Bernd Liesenfeld, Quick-Med's President. "This award is a further validation of our NIMBUS antimicrobial technology platform and will enable us to continue our development a series of products that accelerate wound healing and help prevent microbial contamination."

The new research contract builds on Quick-Med's prior work developing a dressing that was shown to speed healing of vesicant (blister) injuries caused by chemical weapons (sulfur mustard gas). This previous research, which was conducted under Phase 1 and Phase 2 SBIR awards from the US Army, was presented at the 2011 Annual Meeting of the Wound Healing Society, where it received the top prize for Industrial Research and Development. This new award permits Quick-Med to extend that research to more directly address unmet commercial needs in treatments for the approximately 2.4 million thermal burns occurring annually in the US, with a dressing designed to reduce scarring and contracture in healing of severe burns. Part of the research will be conducted at the University of Florida's Institute for Wound Research.

"The NIMBUS super-absorbent polymer technology allows Quick-Med to develop a unique dressing that provides antimicrobial protection for the wound while also acting to minimize scar tissue formation, and inhibit matrix metalloproteinases to block contracture of tissues," said Professor Greg Schultz, Director of the Institute for Wound Research at the University of Florida. "This unique combination therapy should speed healing and reduce contraction of severe burns in our wounded warriors. It would also have extensive application for civilians with large burns."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional and advanced wound care applications, both in the US and abroad. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by numerous U.S. patents and foreign counterparts. Additional applications currently under development include advanced wound dressings, medical adhesives, and catheters.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

A New Solution That Stops Snoring
My Snoring Solution Sponsor
?
© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Contact:
CONTACT:
Quick-Med Technologies
Bernd Liesenfeld
President
[phone]
[e-mail]

[Penny Stocks 2.0]

2013 CONTRACT U.S. ARMY AWARDED>> http://www.google.ca/url?sa=t&source=web&cd=18&ved=0CDAQFjAHOAo&url=http%3A%2F%2Fir.stockpr.com%2Fquickmedtech%2Ffilings%2Fcontent%2F0001140361-13-023080%2F0001140361-13-023080.pdf&ei=ApDXVJnsOITYggTDhYOgCQ&usg=AFQjCNGKDwH79e4KWoZT-d69U13ZUS4I8w

[Penny Stocks 2.0]

Quick-Med's New NIMBUS(R) Advanced Active Wound Dressing Improves Healing

Novel Wound Dressing Developed for U.S. Army Under Small Business Innovation Research Grant
August 10, 2010: 08:00 AM ET

GAINESVILLE, Fla., Aug. 10, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.
Active wound care products combine advanced wound care features such as an antimicrobial barrier with properties that actively promote wound healing and tissue growth. Though still in its infancy, the active wound care segment already accounts for more than $1.5 billion of the $14 billion global wound care market.
Quick-Med scientists have demonstrated significant improvements in wound healing using the NIMBUS Advanced Active dressing in in vitro experiments with chemically injured human tissue. As a next phase of Quick-Med's SBIR research, animal studies using NIMBUS Advanced Active wound dressings have been conducted at Battelle Memorial Institute. When the results of these in vivo studies are reported later this year, Quick-Med expects to see enhanced, complication-free improvements in wound healing based on histological evidence.
"Preliminary findings of the in vivo animal studies demonstrate that NIMBUS Advanced Active can combine actives and control their release to enhance wound healing. These agents can perform additional functions without diminishing the dressing's antimicrobial performance," said Dr. Jerry Olderman, Quick-Med's Vice President of R&D. "NIMBUS Advanced Active is the ultimate multi-functional dressing, with applicability for acute and chronic wounds. Its multiple agents will aid wound healing of many types of acute and chronic injuries. We look forward to receiving the final report on the animal study confirming the results of its healing capabilities."
NIMBUS Advanced Active is a superabsorbent dressing that provides controlled release of a protease inhibitor, antioxidants and epidermal growth factor to stimulate skin regeneration. Derived from Quick-Med's NIMBUS technology, the NIMBUS Advanced Active dressing has broad applicability to all classes of wounds including difficult to treat thermal and chemical burns, and provides a moist wound healing environment with non-leaching antimicrobial protection.
"NIMBUS Advanced Active is a unique wound dressing. There's nothing like it on the market today," said J. Ladd Greeno, Quick-Med's CEO. "We believe that NIMBUS Advanced Active, when commercialized, can significantly aid in the healing process for a wide range of difficult to heal chronic wounds."
Quick-Med will continue to pursue the features of this very unique and flexible active wound dressing as it completes the final report phase of its research work under the U.S. Army SBIR grant. The Company will also seek qualified partners to commercialize its new NIMBUS Advanced Active wound dressing technology.
About NIMBUS®
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received de Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters. NIMBUS Advanced Active is a prototype dressing that has not received FDA clearance.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.
© 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark of Quick-Med Technologies, Inc.
Forward-looking statements (stateme

[Penny Stocks 2.0]

INCREASED FUNDING 2007 Amendment of Solicitation Modification of Contract Between U.s. Army And The R
This is an actual contract by Quick-med Technologies.
Browse the agreement preview below and buy the entire agreement for $35

Sectors: Biotechnology / Pharmaceuticals
Save time and money with our Premium Packages (50% savings)
Search This Document

SECTION SF 30 BLOCK 14 CONTINUATION PAGE



SUMMARY OF CHANGES




SECTION A - SOLICITATION/CONTRACT FORM



The total cost of this contract was increased by $769,999.99 from $70,000.00 to $839,999.99.



The following have been modified:

GOVERNMENT CONTACTSnone

Contract Specialist:





U.S. Army Medical Research Acquisition Activity (USAMRAA

ATTM: MCMR-AAA-R (Mr. Jeff Ingram)

820 Chandler Street

Fort Detrick, MD 21702-5014




Voice: [phone]

FAX: [phone]

Email: [e-mail]





Contracting Officer (KO) (Authorized official to bind the Government in Contracts)





U.S. Army Medical Research Acquisition Activity (USAMRAA)

ATTM: MCMR-AAA (Ms. Pamela Nevels)

820 Chandler Street

Fort Detrick, MD 21702-5014




Voice: [phone]

FAX: [phone]

Email: [e-mail]




Contracting Officer' s Representative (COR) (Government customer/office receiving supplies/services)



USAMRICD

ATTN: MCMR-UV-CC (Dr John Graham)

3100 Ricketts Point Road

Aberdeen Proving Ground

MD, 21010-5400

Voice: [phone]

Email: [e-mail]



RESEARCH TITLE : Chemical Casualty Care: Wound Dressings Designed to Speed Wound Closure Following Debridement of Cutaneous Vesicant Injuries.



TERM OF CONTRACT : Phase I - November 14, 2005 - October 13, 2006 (Research ends May 13, 2005 for base period). The additional 5 months are to allow 1 month for submission of final report and 4 months to allow for Phase II determination. Phase II may or may not be awarded.



Phase I Option period - September 14, 2006 - February 13, 2007 (Research end January 13, 2007)



Phase II - February14, 2007 - March 13, 2009 (Research ends February 13, 2009). The additional month is to allow for submission of final report.



TOTAL CONTRACT VALUE : $840,000.00



FUNDING PROVIDED TO DATE : $385,000.00



PROJECT MANAGER : Dr. Bernd Liesenfeld



CONTRACT TYPE : Firm-Fixed Price


















SECTION B - SUPPLIES OR SERVICES AND PRICES







CLIN 0002

The CLIN extended description has changed from The contractor shall furnish the necessary equipment, personnel, facilities and supplies to conduct the SBIR Phase I research objectives in accordance with the Contract Schedule and the contractor's proposal No. A052-131-1765 Topic A05-131, pages 12-16, wich are incorporated herin by reference. See Section G for payment instructions. to The contractor shall furnish the necessary equipment, personnel, facilities and supplies to conduct the SBIR Phase II research objectives in accordance with the Contract Schedule and the contractor's proposal No. A2-2682, Topic A05-131, is incorporated herin by reference. See Section G for payment instructions. Period of Performance 14 September 2006 - 13 February 2007 (Research end 13 January 2007).

The option status has changed from Option to Option Exercised.



SUBCLIN 000201 is added as follows:



ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 000201 $0.00 FUNDING FFP Additional Funding FOB: Destination PURCHASE REQUEST NUMBER: W81XWH6170M297 NET AMT $0.00 ACRN AC CIN: W81XWH6170M2970001 $40,000.00





CLIN 0004 is added as follows:



ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0004 6 $45,833.33 $275,000.00 SBIR Phase II Year One FFP The contractor shall furnish the necessary equipment, personnel, facilities and supplies to conduct the SBIR Phase II research objectives in accordance with the Contract Schedule and the contractor's proposal No. A052-131-1765 Topic A05-131, pages 12-16, wich are incorporated herin by reference. See Section G for payment instructions. Period of Performance 14 February 2007 - 13 March 2009 (Research ends 13 February 2009) FOB: Destination PURCHASE REQUEST NUMBER: W81XWH6173M321 NET AMT $275,000.00 ACRN AD CIN: W81XWH6173M3210001 $0.00





SUBCLIN 000401 is added as follows:



ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 000401 Funding, Phase II FFP Funding for year one of Phase II FOB: Destination NET AMT $0.00 ACRN AD CIN: 000000000000000000000000000000 $275,000.00





CLIN 0005 is added as follows:



ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 0005 6 $75,833.33 $455,000.00 Phase II Year Two FFP 1c FOB: Destination 1c1c1c1c1c1c1c1c1c1c1c1c1c1c1c1c1c NET AMT $455,000.00

1c1c
















SECTION C - DESCRIPTIONS AND SPECIFICATIONS




The following have been added by full text:



THIS LOCAL CLAUSE IS TO BE INSERTED INTO ALL ARMY OR CBD SBIR or STTR PHASE II AWARDS AT THE TIME THAT THE MODIFICATION, EFFECTING PHASE II, IS ISSUED. THIS LOCAL CLAUSE DOES NOT APPLY TO OSD PHASE II AWARDS. THIS CLAUSE WILL BE IN ADDITION TO THE LOCAL CLAUSE 52.035-4038 REPORTING REQUIREMENTS (WHERE YOU ARE TO INCLUDE MONTHLY, QUARTERLY, AND ANNUAL/FINAL REPORTING REQUIREMENTS FOR ALL PHASE II SBIR or STTR AWARDS).







THIS LOCAL CLAUSE IS TO BE INSERTED INTO ALL ARMY OR CBD SBIR or STTR PHASE II AWARDS AT THE TIME THAT THE MODIFICATION, EFFECTING PHASE II, IS ISSUED. THIS LOCAL CLAUSE DOES NOT APPLY TO OSD PHASE II AWARDS. THIS CLAUSE WILL BE IN ADDITION TO THE LOCAL CLAUSE 52.035-4038 REPORTING REQUIREMENTS (WHERE YOU ARE TO INCLUDE MONTHLY, QUARTERLY, AND ANNUAL/FINAL REPORTING REQUIREMENTS FOR ALL PHASE II SBIR or STTR AWARDS).







RESEARCH AND DEVELOPMENT (R&D) PROJECT SUMMARY - SBIR/STTR PHASE II PROJECT SUMMARY (SEPTEMBER 2006) (USAMRAA)



The contractor shall submit a final, publicly releasable SBIR/STTR Phase II R&D Project Summary at the end of the contract. The summary shall be an unclassified, non-sensitive, and non-proprietary summation of results that is intended for public viewing on the Army SBIR / STTR Small Business Portal. The project summary shall address the data requirements, described below, on a summary basis and shall not exceed 800 words. The summary shall be submitted electronically and shall be in HTML format.



Since the Department of Defense (DOD) will be publishing the summary, this project summary shall not contain any proprietary, classified, or International Traffic in Arms Regulations (ITAR) restricted data.



The Contractor shall deliver one electronic draft "SBIR/STTR Phase II R&D Project Summary" to the Contracting Officer's Representative (COR), with a copy to the Contract Specialist, 23 months after the date of the modification to their contract effecting the commencement of Phase II. The COR shall review the draft report and return it to the Contractor within 15 calendar days of receipt, with any necessary comments. The Contractor shall submit one final "SBIR/STTR Phase II R&D Project Summary," by electronic means, to the COR, with a copy to the Contract Specialist, within 15 calendar days after receipt of the draft comments from the COR, or not later than 24 months after date of modification effecting Phase II (See Website: www.armysbir.comnone .)



Data Requirements - Format and Content Preparation Instructions --



Use, Relationships: none



The R&D Project Summary shall report key project administrative, programmatic, and technical data, to include administrative and research objectives, innovative approaches, accomplishments, plans, technology transitions, technology transfers, and issues. The technical data contained in the R&D Project Summary will enable a comprehensive assessment of project goals, progress and status. The format and content preparation instructions outlined below shall be used for the data product, generated by specific and discrete task requirements as delineated in the contract statement of work (SOW).



Requirementsnone :



1. Project Information.



1.1. Administrative Information.



1.1.1. Subcontractors. Verify each subcontractor.



1.1.2. Performing Organization Contacts.



1.1.2.1. Principal Investigator(s) Contact. Verify the name, organization, business address, business phone, business fax, and e-mail address of each principal investigator.



1.1.2.2. Administrative Contact. Verify the name, organization, business address, business phone, business fax, and e-mail address of the administrative point of contact.



1.1.2.3. Reserved.



1.1.2.4. Programmatic/Technical Reporter Contact. If the Principal Investigator is not the reporter of the programmatic/technical data verify the name, organization, business address, business phone, business fax, and e-mail address of the programmatic/technical reporter point of contact.



1.2. Programmatic Information.



1.2.1. Project Uniform Resource Locator (URL). Provide the project URL.



1.2.2. Project Description.



1.2.2.1. Research Objectives.



1.2.2.2. Problem Description. Provide a concise description of the problem area addressed by this research project.



1.2.2.2.1. Research Goals. Identify specific research goals of this project. Identify and quantify expected performance improvements from this research. Identify new capabilities enabled by this research. Identify and discuss salient features and capabilities of developmental hardware and software prototypes.



1.2.2.2.2. Expected Impact. Describe the expected impact of the research project, if successful, to the problem area.



1.2.2.3. Technical Approach.



1.2.2.3.1. Detailed Description of Technical Approach. Provide a detailed description of the technical approach that was used in this project to achieve the research goals. Specifically identify and discuss innovative aspects of the technical approach.



1.2.2.3.2. Comparison with Current Technology. Describe state-of-the-art approaches and the limitations within the context of the problem area addressed by this research.



1.2.2.4. Schedule and Milestones.



1.2.2.4.1. Schedule Graphic. Provide a graphic representation of the project schedule. Show all project milestones. Use absolute time designations for all dates.



1.2.2.4.2. Reserved.



1.2.2.5. Deliverables Description. List and provide a description for each planned deliverable and expected delivery dates for each deliverable.



1.2.2.6. Technology Transition and Technology Transfer Targets and Plans. Discuss plans for technology transition and transfer. Identify specific military and commercial organizations for technology transition or transfer. Specify anticipated dates for transition or transfer.




1.2.2.7. Quad Chart. Provide a Quad Chart as one (1) landscape-oriented page divided into four quadrants and suitable for use in briefings using the following format:



PROJECT TITLE



______________________________________________________________________________________

GRAPHIC: | NEW IDEAS:

|

A visually compelling graphic that | List new technical ideas embodied

conveys the key technological idea(s) | by the research.

or the expected impact of the research. |

|

______________________________________________________________________________________

IMPACT: | SCHEDULE:

|

Quantitative statements discussing how | Use absolute time designations

this research can revolutionize an area of | for all dates.

importance to the Department of Defense. |

______________________________________________________________________________________





2. Reserved.



3. Technical Report.



3.1. Project Progress.



3.1.1. Progress Against Planned Objectives. Update the status of the specific objectives. For each objective, indicate if the objective was or was not accomplished. For each objective not accomplished, detail the current status of the objective.



3.1.2. Technical Accomplishments this Period. Describe the technical accomplishments made.



3.1.3. Improvements to Prototypes this Period. Provide a detailed, quantitative description of significant new features, capabilities and performance enhancements to hardware and software prototypes made.



3.1.4. Significant Changes to Technical Approach to Date. Identify and provide a detailed description of and rationale for significant changes to the technical approach since the start of the research project.



3.1.5. Deliverables this Period. Report the deliverables (excluding Technology Transition and Transfer covered under 3.1.6.) submitted. List the Deliverable Name, Type of Deliverable (e.g. hardware or software item, demonstration, milestone, design study or other documentation), and Date of Submission. Specify the organization that received the deliverable.



3.1.6. Technology Transition and Transfer this Period.



3.1.6.1. Technology Transition and Transfer Description. List and describe the features and performance capabilities for each technology transitioned or transferred.



3.1.6.2. Technology Transition and Transfer List. For each technology transitioned or transferred, identify the specific military, commercial, or other transition or transfer organization(s) and the application context.



3.1.6.3. Technology Transition and Transfer Contacts. For each technology transitioned or transferred, specify the , organization that received the transitioned or transferred technology.



3.1.7. Reserved.



3.1.8. Reserved.



3.1.9. Issues or Concerns. Summarize any funding, technical, programmatic, or other issues or concerns as well as recommended actions for consideration.



3.2. Project Plans.



3.2.1. Planned Activities. Describe the planned activities. Discuss the risks and payoffs corresponding to the planned activities. Include a discussion of planned experiments, demonstrations, presentations, and technical papers.



3.2.2. Reserved.




















-- End of Preview --

View other agreements from Quick-med Technologies Agreements
Quick Med Technologies - 2009 Senior Convertible Note Issued To Michael Granito
Quick Med Technologies - 2009 Senior Convertible Note 3 Issued To Michael Granito
Quick Med Technologies - 2009 Senior Convertible Note 2 Issued To Michael Granito
Quick Med Technologies - 2008 Senior Convertible Note 3 Issued To Michael Granito
Above Average - Amendment To Merger Agreement
Home| About Us| FAQ| Subscription | Contact Us |
Privacy Policy Terms of Service

© Copyright Socratek L.L.C. 2011

[Penny Stocks 2.0]

PHASE 2 Quick-Med Technologies, Inc. (OTCBB: QMDT) (the "Company") today confirmed receipt of a Phase II Small Business Innovative Research ("SBIR") grant of $770,000 from the U.S. Army. The contract continues the Company's innovative research intended to develop a prototype wound dressing to speed healing of wounds from chemical blistering agents. The wound dressing being developed is based on advancements in the Company's NIMBUS(TM) technology. On July 26, 2006 the Company announced that it had been competitively selected for this grant, subject to availability of Federal funds and successful contract negotiations. Today's announcement confirms amounts and completion of the contract.

The NIMBUS technology process permanently binds polymeric antimicrobial onto surfaces that include cellulosics such as cotton and rayon, as well as various synthetics. This process enables the economical preparation of high performance wound dressings, fabrics and other medical and consumer products.

"We are very pleased with this Phase II grant from the U.S. Army," commented David S. Lerner, president of Quick-Med Technologies. "This grant will accelerate our development of advanced wound care products."

During Phase I of the grant, Quick-Med Technologies completed feasibility studies and proof of concept. The Phase II SBIR grant is worth $770,000, including $40,000 of additional funding under a Phase I (option) invoked by the U.S. Army. The total value of this contract for Phase I, Phase I (option), and Phase II is $840,000. Work under this contract is expected to be completed by 2009.

This work is supported by the U.S. Army Medical Research and Material Command under Contract No. W81XWH-06-C-0024. The Department of Defense's SBIR program was developed to stimulate technological innovation to meet military as well as commercial needs.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Quick-Med Technologies, Inc. is a life sciences company focused on developing broad-based technologies within the healthcare and consumer markets. The Company's two core products under development are the (1) NIMBUS(TM), a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products; and (2) MultiStat(TM) family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets. Quick-Med Technologies, Inc. is listed under the symbol "QMDT" on the OTC Bulletin Board.

For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at [e-mail]. For Details, Contact: Natasha A. Sorobey at [phone]

(C) 2006 Quick-Med Technologies, Inc. All rights reserved. NIMBUS (TM) and MultiStat (TM) are trademarks of Quick-Med Technologies, Inc. All other trademarks are the property of their respective owners.

[Penny Stocks 2.0]

US ARMY FUNDING QUICK-MED TECHNOLOGIES FORM 8-K US ARMY GRANT



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 18, 2006


QUICK-MED TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)


Nevada
000-27545
98-0204736
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)


3427 SW 42nd Way
Gainesville, Florida
32608
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code [phone]

___________________________________________________________________________________________________________
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement

The following discussion provides only a brief description of the document described below. The discussion is qualified in its entirety by the full text of the agreement, which is attached to this Current Report on Form 8-K as an exhibit.

On September 18, 2006 the Registrant entered into an Amendment of Solicitation / Modification of Contract with the U.S. Army Medical Research Acquisition Activity Department in which the U.S. Army authorized the release of an additional $770,000 to the Registrant to further pursue Quick-Med’s research regarding the development of a prototype wound dressing to speed healing of wounds from chemical blistering agents. This funding is made under the U.S. Army’s Small Business Innovation Research Program. At the end of the Phase II project, the Registrant shall submit a final, publicly releasable Phase II R&D Project Summary at the end of the contract.


Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

Exh. No. Description


10.1
Amendment of Solicitation / Modification of Contract between U.S. Army and the Registrant dated September 18, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


QUICK-MED TECHNOLOGIES, INC.

(Registrant)

Date: September 25, 2006


/s/ David Lerner

David Lerner, President

[Penny Stocks 2.0]

Older But Time Line is Key >> Quick-Med Technologies, Inc. Awarded U.S. Army SBIR Phase I Contract

November 15, 2005 06:00 AM Eastern Standard Time

GAINESVILLE, Fla.--(BUSINESS WIRE)--Nov. 15, 2005--Quick-Med Technologies, Inc., (OTCBB:QMDT) ("Quick-Med Technologies" or "QMT"), announced today that the United States Army Small Business Innovative Research ("SBIR") has competitively awarded a Phase I contract (W81XWH-06-C-0024) to Quick-Med Technologies titled: Chemical Casualty Care: Wound Dressing to Speed Wound Closure Following Debridement of Cutaneous Vesicant Injuries.

Under the Phase I contract, the Company will design a prototype wound dressing using advancements in the NIMBUS(TM) technology to speed the healing of wounds from chemical blister agents.

NIMBUS(TM) is a highly effective non-toxic, and extremely cost effective, microbicidal agent that can be permanently bonded to materials such as cotton, cotton blends or polyurethane to create advanced wound dressings, fabrics, or other medical, or consumer products.

"This SBIR will allow QMT to validate this core technology with a critical user, the Department of Defense medical community, and solve a long standing challenge for the Department of Defense -- the treatment of vesicant wounds." said Maj. Gen. George E. Friel (Ret.), Vice President of Chemical & Biological affairs of Quick-Med Technologies.

Chemical warfare agents such as sulfur mustard and Lewisite induce blistering skin injuries, which can vary in severity between second degree and third degree. These injuries can take several months to heal, necessitate lengthy hospitalizations, and result in significant cosmetic and/or functional deficits. There are currently no standardized or optimized methods of casualty management that prevent or minimize deficits and provide for speedy wound healing. Recent advances have been made in improving the healing of these skin injuries using a variety of techniques to debride (remove) damaged tissue, including the use of medical lasers. Following debridement of deep injuries (third degree), skin grafting is required. Following debridement of more superficial injuries (second degree), the cleansed wounds need to be covered with a dressing that will minimize wound contraction and scar tissue formation, and promote ingrowth of new skin cells (keratinocytes) to cover the wound in a process known as re-epithelialization. The increased speed of wound healing afforded by debridement can be further improved through the use of an appropriate wound dressing that can provide a moist wound healing environment, absorb moderate amounts of wound fluids (exudates), provide antibacterial action, control the action of protein dissolving enzymes (proteases), and deliver nutritive substances and growth factors.

Many wound-healing dressings require frequent changes, thereby inflicting added burden on the medical logistical system. Similarly, additions of various growth factors, antiproteases, and nutritive substances have been shown to be beneficial when added to the wound bed. There is a need for a product, which can be used to treat chemical casualties that combine the features of several of these products. The current effort would use existing technology or products to develop a single, new dressing with all of these features. This is expected to be technically challenging, and will require innovative and creative approaches to meet the technical goals.

For use in battlefield scenarios and upper echelon medical facilities, such a product should have a long shelf life (e.g., 1 year), and not require special storage conditions (e.g., freezing).

The aim of this effort is to design a wound dressing that will return damaged skin to optimal appearance and normal function in the shortest time. Improved treatment will result in a better cosmetic and functional outcome for the patient, and a speedier return to duty, thereby decreasing medical logistical burden, sustaining operational tempo, and deterring use by enemy forces.

PHASE I: Develop overall design of wound dressing, with preliminary in vitro or in vivo proof-of-concept experiments showing promising results.

PHASE II: Develop and demonstrate efficacy of a prototype wound dressing. Conduct in-depth testing in an appropriate animal wound-healing model, comparing prototype dressing with a standard moisture-retentive dressing.

PHASE III DUAL USE APPLICATIONS: This wound dressing could be used in a broad range of military and civilian medical settings. Dressing would benefit military and civilian patients suffering from vesicant burns, thermal burns, and chronic skin ulcers such as decubitus ulcers, venous stasis ulcers, arterial insufficiency ulcers, and diabetic foot ulcers.

Note: The entire June 15, 2005 solicitation may be viewed at: http://www.sbirworld.com//solicitations/sbres/sbhist/dod/army/armysbir05_%20a05-131.htm (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).

About Three-Phased Program

Companies apply first for a phase I award of up to $100,000 to test the scientific, technical, and commercial merit and feasibility of a particular concept. If phase I proves successful, the company may be invited to apply for a two-year phase II award of up to $750,000 to further develop the concept, usually to the prototype stage. Proposals are judged competitively on the basis of scientific, technical, and commercial merit. Following completion of phase II, small companies are expected to obtain funding from the private sector and/or non-SBIR government sources to develop the concept into a product for sale in private sector and/or military markets.

About SBIR Program

The Small Business Innovation Research program is a Congressionally-mandated program which was established in 1982 to increase the participation of small businesses in federal research and development ("R&D"). The Department of Defense program, funded at approximately $1.079 billion in FY 2005, is made up of 10 participating components: Army, Navy, Air Force, Missile Defense Agency, Defense Advanced Research Projects Agency, Chemical Biological Defense, Special Operations Command, Defense Threat Reduction Agency, National Geospatial-Intelligence Agency, and the Office of Secretary of Defense. The SBIR program funds early-stage R&D at small technology companies and is designed to: (i) stimulate technical innovation; (ii) increase private sector commercialization of federal R&D; (iii) increase small business participation in federal funded R&D; and (iv) foster participation by minority and disadvantaged firms in technical innovation.

About Quick-Med Technologies, Inc.

Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company's two core products under development are: (1) MultiStat(TM), a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS(TM), a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at [e-mail]. For Details, Contact: David S. Lerner, President at 561-750-4202. For Investor Relations, Contact: Natasha A. Sorobey at 561-208-8259

[Bruce the Stock Guy]

QMDT..Couple of whales(no offense) coming in I hear!

[Bruce the Stock Guy]

QMDT..Our partner is kind of a big deal!>>>>Avery Dennison Announces Fourth Quarter and Full Year 2014 Results
4Q14 Reported EPS (including discontinued operations) of $0.76
Adjusted EPS (non-GAAP, continuing operations) of $0.90
4Q14 Net sales grew approximately 1 percent on reported and organic basis to $1.6 billion
FY14 Reported EPS (including discontinued operations) of $2.60
Adjusted EPS (non-GAAP, continuing operations) of $3.11
FY14 Net sales grew approximately 3 percent on reported and organic basis to $6.3 billion
Expect FY15 Reported EPS of $2.95 to $3.15
Adjusted EPS (non-GAAP) of $3.20 to $3.40

[Bruce the Stock Guy]

$QMDT..What do you think about our relationship with this GIANT?>>>> Avery Dennison Medical Solutions and Quick-Med Technologies Successfully Develop New, High-Performance Antimicrobial Adhesive

Avery Dennison Medical Solutions Expands Technology Platform; Licenses NIMBUS(R) From Quick-Med

CHICAGO and GAINESVILLE, Fla., April 12, 2011 (GLOBE NEWSWIRE) -- Avery Dennison Medical Solutions, a division of Avery Dennison Corporation (NYSE:AVY) and a global leader in pressure-sensitive adhesive technologies for medical applications, in partnership with Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that develops innovative technologies for healthcare and consumer markets, today announced the completion of a license agreement for Quick-Med's NIMBUS® technology. The announcement comes after Avery Dennison Medical Solutions' successful development of a new antimicrobial adhesive featuring NIMBUS technology that can be incorporated into a variety of medical device applications, including surgical, wound care and vascular access products. The antimicrobial adhesive can be effective across multiple organisms even in the presence of large amounts of serum and body fluids.

"We are advancing our antimicrobial technology platform to provide innovative solutions that answer the needs of medical device providers and patients worldwide," said Howard Kelly, Vice President and General Manager, Avery Dennison Medical Solutions. "The success of our partnership with Quick-Med is a key component of our progress in this segment. We look forward to expanding our antimicrobial offerings and accelerating our growth now that the license agreement is in place."

Under a joint development agreement initiated in April 2009, the two companies worked in close collaboration to incorporate Quick-Med's proprietary NIMBUS antimicrobial technology into Avery Dennison Medical Solutions' adhesive technologies for medical device applications. NIMBUS is non-toxic, non-leaching and non-depleting, and is designed to eliminate the risk of bacterial resistance issues.

"Successful development of the antimicrobial adhesive and completion of the license agreement with Avery Dennison Medical Solutions, an industry leader and innovator, further validates the potential of Quick-Med's technologies for a range of applications," said J. Ladd Greeno, CEO of Quick-Med Technologies. "This valuable partnership will continue to leverage the combination of Avery Dennison Medical Solutions' inventive adhesive technologies with our highly effective, non-toxic, long-lasting, non-leaching and affordable antimicrobial protection, for the multi-billion dollar global medical adhesives market."

About Avery Dennison

Avery Dennison (NYSE:AVY) helps make brands more inspiring and the world more intelligent. For more than 75 years the company has been a global leader in pressure-sensitive technology and materials, retail branding and information solutions, and organization and identification products for offices and consumers. A FORTUNE 500 company with sales of $6.5 billion in 2010, Avery Dennison is based in Pasadena, California and has employees in over 60 countries. For more information, visit www.averydennison.com.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a persistent hand sanitizer. For more information, see: www.quickmedtech.com.

[Bruce the Stock Guy]

QMDT..Our investor and public relations firm>>>>About Match Point Partners LLC

Headquartered in New York City, Match Point Partners is a strategy and financial advisory firm that provides a unique blend of value-added strategic, operating and investment banking services to emerging middle market healthcare and technology firms. Our team of experienced entrepreneurs, bankers, and operators collaborate to develop and execute creative, innovative and often out-of-the-box solutions to help our clients achieve superior value. All securities are offered through Bridge Capital Associates, Inc., Member FINRA / SIPC. For more information, please visit www.mppartnersllc.com.

[Bruce the Stock Guy]

QMDT..How about a contract with the ARMY? Go ARMY!>>>>GOVERNMENT CONTACTS
Contract Specialist:

U.S. Army Medical Research Acquisition Activity (USAMRAA)
ATTN: MCMR-AAA-G Shavon Baker
820 Chandler Street
Fort Detrick, MD 21702-5014

Voice: [phone]
Fax: [phone]
Email: [e-mail]

Contracting Officer (KO) (Authorized Official to bind the Government in Contracts):

U.S. Army Medical Research Acquisition Activity (USAMRAA)
ATTN: MCMR-AAA-S (Ms. Micaela Bowers)
820 Chandler Street
Fort Detrick, MD 21702-5014

Voice: [phone]
Fax: [phone]
Email: [e-mail]

Contracting Officer's Representative (COR) (Government customer/office receiving services/supplies):

USAMMDA
ATTN: Luis Alvarez
1564 Freedman Drive
Fort Detrick, MD 21702

Voice: 301-619-8429
Email: [e-mail]

[Bruce the Stock Guy]

$QMDT..How about QMDT with a market cap of 1.5 million-INSANELY UNDERVALUED!?>>>>Biotech (positive) 
The demand  and growth of the health  care industry is  easy 
enough to see. The developed world has an aging population 
which easily bakes in increased demand for services and drugs. 
Add to this an increased reliance on large pharmaceuticals to 
feed their drug pipelines  via  acquisition instead of in house 
research and development, and the long term stage is set for 
the biotechs.  
 Shorter term, the financial crisis has weighed on the industry.  
Over half of the U.S. listed  biotech  companies now have  a 
market  capitalization  below  U$100  million.  Plus,  as  new 
capital has dried up, there are a high number of companies 
without or running low on  cash. Investing where  capital is 
scarce can offer investors much better entry points and terms 
compared  to  industries  where  capital  is  more  plentiful. 
Finding  companies  with  promising  drugs  and  cash  on the 
balance  sheet  in  this  beaten  down  industry  is  crucial  for 
success.

[Bruce the Stock Guy]

QMDT..On our lenders website and executed to perfection by QMDT!>>>>“I was once ask if a big business man ever reached his objective. I replied that if a man ever reached his objective he was not a big business man.”

Charles M. Schwab

[Bruce the Stock Guy]

QMDT..Its all about the numbers..37 mil O/S with PPS at 04-ZERO dilution and only 38 followers = 90 day projected 82 followers,same O/S and PPS of .39ish imo

[Bruce the Stock Guy]

$QMDT..Wound care is a 14 BILLION DOLLAR industry in itself!>>>The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing.

[Bruce the Stock Guy]

$QMDT..Rubbing elbows with some bigtime players!>>>>AVERY DENNISON, BASF, DERMA SCIENCE..

[Papa Bear]

TY for that! #QMDT!

[Bruce the Stock Guy]

QMDT..Welcome Gemstone..You chose well..

[Penny Stocks 2.0]

Welcome aboard Gemstone, grabbed a mod spot I see, awesome team forming!!!

[Penny Stocks 2.0]

17m-20m RESTRICTED.

[Penny Stocks 2.0]

100m A/S, 37m O/S with 19m FLOAT

[Bruce the Stock Guy]

QMDT..Good idea..This one has ZERO dilution,o/s of 37 mil with STRONG connections and possibilities!

[gemstone57]

QMDT taking a position monday afternoon

[gemstone57]

Stay Fresh !!! QMDT

[tradeho]

Well I neither agree or disagree with you, I ask for more than options. I do agree with your comment regarding desperate people.

[gemstone57]

whats the current SS

[gemstone57]

I like this it looks to have great poential

[Bruce the Stock Guy]

QMDT..Big welcome to Papa Bear as QMDT Mod!

[Bruce the Stock Guy]

QMDT..Welcome..You chose well..

[Papa Bear]

Glad to have you here bud .... QMDT!

[reconranger]

Bought a few yesterday based on the hype. Think we have a winner here folks. Thanks for the solid DD. Will be adding to my starter position next week.-reconranger

[Penny Stocks 2.0]

INTELLECTUAL PROPERTIES, Competition Expired Proof >>>

[Penny Stocks 2.0]

COMPETITIVE ADVANTAGES >>>

[Penny Stocks 2.0]

HUGE STICKY PLZ >>>

[Papa Bear]

QMDT: Four whole pennies! It is unbelievable to think about that!

[ZIA SPIRIT]

Watching closely to add. This will be one crazy unpredictable ride

[Penny Stocks 2.0]

HUGE DEAL >>> Quick-Med Signs License With Medline to Provide Stay-Fresh(R) Antimicrobial Technology for Traditional Wound Care Products

GAINESVILLE, FL -- (Marketwired) -- 02/28/14 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has licensed its Stay Fresh® technology to Medline Industries, Inc. for use in traditional wound care products for both retail and institutional sale in the North American market.

"We are very excited to work together with Medline to commercialize our Stay Fresh® technology for the traditional wound care market," said Bernd Liesenfeld, Quick-Med's President. "Our technologies are specifically designed to be effective against resistant organisms like MRSA and to prevent new resistant bacteria from emerging. Medline has an unparalleled distribution network between retail and institutional sectors. They allow us together to provide the greatest possible population with safe, effective antimicrobial products in support of infection prevention and control programs."

"Stay Fresh antimicrobial activity is based on peroxide, which is the chemical mechanism utilized by the body's own neutrophils to kill invading pathogens, and therefore provides optimum biological safety," notes Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "This is an exciting new technology that is well suited for the traditional wound care field since peroxide is effective against a broad array of microbes, including antibiotic resistant species of public health importance, while also posing little risk of allowing microbes to develop resistance to it." 

About Stay Fresh
The patented Stay Fresh technology is Quick-Med's newest antimicrobial platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously with development of additional applications, including antimicrobial surface treatments and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

About Medline
As the nation's largest privately held manufacturer and distributor of health care products, Medline manufactures and distributes more than 350,000 products to hospitals, extended care facilities, surgery centers, physician offices, home care agencies and providers, and retailers. Named one of the country's "Best and Brightest Companies to Work For," Medline, headquartered in Mundelein, Ill., has more than 1,200 dedicated sales representatives to support its broad product line and cost management services.. For more information on Medline, go to www.medline.com or http://mkt.medline.com/clinical-blog/category/channels/social-channels/ to connect with Medline on a variety of social media channels.

© 2014 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.

[Penny Stocks 2.0]

Avery Dennison (NYSE) $50+, BASF (QX) $90, DERMA SCIENCE (NASDAQ) $8+, QMDT (OTC) $0.04! All connected plus the GIANT MEDLINE who is private with $5+ billion in Annual sales. Many many more....

[tk2007]

I hope that's the case. Then we all will be rewarded big here.

[Penny Stocks 2.0]

Possibly a merger in place, with these connections its very possible.

[tk2007]

Why did they file 15-12G in 2013? the company won't have to file to SEC any more, this may be the reason the pps was down, other than that, it should trade in the dollars.

[Bruce the Stock Guy]

QMDT..It's 04 papa..Think about that..

[Papa Bear]

You know how that is .... any fly by night POS company can get them! NOT #QMDT!

[Bruce the Stock Guy]

QMDT..AD would be my pick..Fatness!

[Papa Bear]

QMDT: HUGE opportunity for those traders that can see what is right in front of them

[Penny Stocks 2.0]

Partners AVERY DENNISON, BASF, DERMA SCIENCE, POLARTEC, VIRIDIS, DORIS BIOSARA, WEXLER....Who wants FULL OWNERSHIP?